A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-Facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
EClinicalMedicine - United Kingdom
doi 10.1016/j.eclinm.2018.12.006
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2019
Authors
Publisher
Elsevier BV